Vaccine-Induced HIV Seropositivity/Reactivity in Noninfected HIV Vaccine RecipientsCOOPER, Cristine J; METCH, Barbara; DRAGAVON, Joan et al.JAMA, the journal of the American Medical Association. 2010, Vol 304, Num 3, pp 275-283, issn 0098-7484, 9 p.Article

Determinants of enrollment in a preventive HIV vaccine trial: Hypothetical versus actual willingness and barriers to participationBUCHBINDER, Susan P; METCH, Barbara; HOLTE, Sarah E et al.Journal of acquired immune deficiency syndromes (1999). 2004, Vol 36, Num 1, pp 604-612, issn 1525-4135, 9 p.Article

Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b studyGRAY, Glenda E; ALLEN, Mary; ROUX, Surita et al.Lancet. Infectious diseases (print). 2011, Vol 11, Num 7, pp 507-515, issn 1473-3099, 9 p.Article

Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccinesMONTEFIORI, David C; METCH, Barbara; MCELRATH, M. Juliana et al.The Journal of infectious diseases. 2004, Vol 190, Num 11, pp 1962-1969, issn 0022-1899, 8 p.Article

Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili studyGRAY, Glenda E; MOODIE, Zoe; MNGADI, Kathryn et al.Lancet. Infectious diseases (print). 2014, Vol 14, Num 5, pp 388-396, issn 1473-3099, 9 p.Article

Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for DeliveryKALAMS, Spyros A; PARKER, Scott D; FUCHS, Jonathan et al.The Journal of infectious diseases. 2013, Vol 208, Num 5, pp 818-829, issn 0022-1899, 12 p.Article

Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trialSPEARMAN, Paul; KALAMS, Spyros; FREY, Sharon E et al.Vaccine. 2009, Vol 27, Num 2, pp 243-249, issn 0264-410X, 7 p.Article

Risk behavior among women enrolled in a randomized controlled efficacy trial of an adenoviral vector vaccine to prevent HIV acquisitionNOVAK, Richard M; METCH, Barbara; SOBIESZYCZ, Magda et al.AIDS (London). 2013, Vol 27, Num 11, pp 1763-1770, issn 0269-9370, 8 p.Article

The HVTN Protocol 903 Vaccine Preparedness Study : Lessons Learned in Preparation for HIV Vaccine Efficacy TrialsDJOMAND, Gaston; METCH, Barbara; BEYRER, Chris et al.Journal of acquired immune deficiency syndromes (1999). 2008, Vol 48, Num 1, pp 82-89, issn 1525-4135, 8 p.Article

Feasibility of Identifying a Cohort of US Women at High Risk for HIV Infection for HIV Vaccine Efficacy Trials: Longitudinal Results of HVTN 906KOBLIN, Beryl A; METCH, Barbara; FRANK, Ian et al.Journal of acquired immune deficiency syndromes (1999). 2013, Vol 63, Num 2, pp 239-244, issn 1525-4135, 6 p.Article

Impact of anti-orthopoxvirus neutralizing antibodies induced by a heterologous prime-boost HIV-1 vaccine on insert-specific immune responsesWALSH, Stephen R; SEAMAN, Michael S; GRANDPRE, Lauren E et al.Vaccine. 2012, Vol 31, Num 1, pp 114-119, issn 0264-410X, 6 p.Article

A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjectsKEEFER, Michael C; FREY, Sharon E; PHILIPPON, Valérie et al.Vaccine. 2011, Vol 29, Num 10, pp 1948-1958, issn 0264-410X, 11 p.Article

Lessons from a multisite international trial in the caribbean and south America of an HIV-1 canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120CLEGHORN, Farley; PAPE, Jean W; MONTEFIORI, David C et al.Journal of acquired immune deficiency syndromes (1999). 2007, Vol 46, Num 2, pp 222-230, issn 1525-4135, 9 p.Article